Scoop: Caris­ma stole CAR-M Thun­der for a while, but a Utah biotech is qui­et­ly rais­ing funds to en­ter the fray

There’s calm be­fore the storm. And there’s calm af­ter the storm.

That’s the case for a Utah biotech that for years has flown un­der the CAR-M radar, be­ing out­paced by the likes of Mod­er­na-al­lied Caris­ma Ther­a­peu­tics. The up­start worked calm­ly, put walls around its IP and pur­pose­ful­ly steered clear of talks with in­sti­tu­tion­al in­vestors and phar­mas be­fore it would open its doors to a po­ten­tial storm of at­ten­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER